Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Cook

Interventional Pain Medicine Brownsburg, IN Medical Doctor

NPI 1083956239 CMS profile 1398437

7950 Ortho Ln, Brownsburg, IN 46112

Open in the dashboard

General payments

$11,812

274 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Cook of Brownsburg, IN is reported in the CMS Open Payments database as having received $11,812 across 274 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,157 47
2024 General $1,468 88
2023 General $667 22
2022 General $832 20
2021 General $1,506 28
2020 General $1,017 15
2019 General $5,166 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Cook
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Andrew Cook were reported at $1,157. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Andrew Cook Interventional Pain Medicine median Middle half National median
2019 $5,166 $684 $216–$2,079 $163
2020 $1,017 $382 $122–$1,109 $114
2021 $1,506 $552 $167–$1,554 $132
2022 $832 $605 $187–$1,924 $149
2023 $667 $671 $195–$1,915 $160
2024 $1,468 $684 $206–$1,837 $164
2025 $1,157 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,637 52 payments
  2. Vertiflex, Inc. $1,897 11 payments
  3. Relievant Medsystems, Inc. $1,037 8 payments
  4. Medtronic USA, Inc. $735 8 payments
  5. Boston Scientific Corporation $696 42 payments
  6. ANI Pharmaceuticals, Inc. $524 20 payments
  7. Nevro Corp. $454 7 payments
  8. AbbVie, Inc. $411 34 payments
  9. Vertos Medical, Inc. $389 8 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $371 18 payments
  11. Other $1,661 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,556 266 payments
  2. Travel and Lodging $2,241 7 payments
  3. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. Superion ISS $1,897 11 payments
  2. Proclaim Family of SCS IPGs $1,751 26 payments
  3. Proclaim IPG $1,293 16 payments
  4. Intracept $1,014 6 payments
  5. OSTEOCOOL RF ABLATION $720 7 payments
  6. WaveWriter Alpha Prime 16 $541 38 payments
  7. PURIFIED CORTROPHIN GEL $524 20 payments
  8. Senza Spinal Cord Stimulation System $454 7 payments
  9. mild Device Kit $338 6 payments
  10. UBRELVY $288 24 payments
  11. Other $3,261 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,969

Median for Pain Management: 951

Drug cost

$84,654

Median for Pain Management: $26,034

Branded share of claims

49.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 849 $19,397
Belbuca Buprenorphine Hcl Brand 14 $13,716
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 461 $13,642
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 33 $6,512
Pregabalin Generic 259 $5,711
Gabapentin Generic 270 $4,169
Buprenorphine Generic 12 $3,954
Oxycodone Hcl Generic 154 $2,968
Morphine Sulfate Er Morphine Sulfate Brand 67 $2,047
Fentanyl Generic 12 $1,298

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$123,943

Of which drugs: $858

Medicare patients

273

Average age 72

Services billed

2,693

182 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 45%
Diabetes 41%
Ischemic heart disease 34%
Chronic kidney disease 32%
Osteoporosis 28%
Heart failure 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 252 $181
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 858 $89

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $291
$291 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $243
$243 — —
UBRELVY
  • AbbVie, Inc. $132
$132 — —
QULIPTA
  • AbbVie, Inc. $97
$97 — —
NURTEC ODT
  • PFIZER INC. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

274 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record